CCL2 inhibition through anti-CCL2 monoclonal antibodies (mAb) has also experienced success in reducing the population of MDSCs and improving survival in GBM xenograft models (Zhu et al., 2011). This evidence concerns the gene CCL2 and glioblastoma.